Revive Therapeutics Adds Turkish Subjects To Bucillamine Phase 3 Clinical Trial For COVID-19

Revive Therapeutics (CSE: RVV) announced on Wednesday that it has expanded its phase 3 clinical trial for oral drug bucillamine as a treatment for COVID-19. The firm has decided to fill a part of its patient enrollment quota in the trial with subjects outside the US, specifically from Eastern Europe such as patients in Turkey.

The middle eastern country is currently experiencing high infection rates for the pandemic disease, reporting 32,176 new daily cases on December 28, 2021 alone.

The move is also meant “to ensure a diversified patient population to support future global regulatory submissions.”

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

To date, the trial has screened approximately 700 subjects while no serious adverse events and safety concerns reported were reported so far.

The biotech firm is targeting to complete the study by Q1 2022 and is expected to file for Emergency Use Authorization with the US FDA following the trial’s results.

Earlier this month, the study also expanded to include the emerging Omicron variant of SARS-CoV-2 in its phase 3 clinical trial.

Revive Therapeutics last traded at $0.40 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a former client of Canacom Group, the parent company of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Selkirk Copper Wraps 54,579 Metre Phase 2 Program at Minto, Hits 5.97% Copper Equivalent

Related News

Revive Therapeutics Applies For Orphan Drug Designation For Psilocybin

Revive Therapeutics (CSE: RVV) has filed for orphan drug designation with the US Food and...

Tuesday, April 27, 2021, 09:34:32 AM

Three Things to Know About ‘Phase 3 COVID Player’: Revive Therapeutics

Bucillamine Just Got Cleared for Phase 3 Trials of COVID-19 On Friday, July 31, 2020...

Monday, August 3, 2020, 10:11:55 AM

Revive Appoints Infectious Disease Expert As Scientific Adviser

Revive Therapeutics (CSE: RVV) this morning announced that they have appointed Dr David Boulware as...

Tuesday, March 24, 2020, 10:35:22 AM

Revive Files Clinical Trial Application With Health Canada, Releases Phase 3 FDA Study Design For Potential Treatment Of COVID-19

Revive Therapeutics (CSE: RVV) continues to advance its clinical trial efforts. The company announced this...

Wednesday, June 3, 2020, 11:30:38 AM

Revive Therapeutics Conducts $10.0 Million Bought Deal Financing

Revive Therapeutics (CSE: RVV) this evening announced that it will be conducting a bought deal...

Wednesday, January 20, 2021, 08:37:25 PM